Context Therapeutics (CNTX) Competitors $0.63 -0.02 (-3.77%) As of 09:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTX vs. AVTE, YMAB, ACTU, ENGN, SCPH, CTMX, DRUG, CRGX, IPHA, and NBTXShould you be buying Context Therapeutics stock or one of its competitors? The main competitors of Context Therapeutics include Aerovate Therapeutics (AVTE), Y-mAbs Therapeutics (YMAB), Actuate Therapeutics (ACTU), enGene (ENGN), scPharmaceuticals (SCPH), CytomX Therapeutics (CTMX), Bright Minds Biosciences (DRUG), CARGO Therapeutics (CRGX), Innate Pharma (IPHA), and Nanobiotix (NBTX). These companies are all part of the "pharmaceutical products" industry. Context Therapeutics vs. Its Competitors Aerovate Therapeutics Y-mAbs Therapeutics Actuate Therapeutics enGene scPharmaceuticals CytomX Therapeutics Bright Minds Biosciences CARGO Therapeutics Innate Pharma Nanobiotix Context Therapeutics (NASDAQ:CNTX) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and community ranking. Does the MarketBeat Community prefer CNTX or AVTE? Context Therapeutics received 9 more outperform votes than Aerovate Therapeutics when rated by MarketBeat users. Likewise, 80.00% of users gave Context Therapeutics an outperform vote while only 54.29% of users gave Aerovate Therapeutics an outperform vote. CompanyUnderperformOutperformContext TherapeuticsOutperform Votes2880.00% Underperform Votes720.00% Aerovate TherapeuticsOutperform Votes1954.29% Underperform Votes1645.71% Is CNTX or AVTE more profitable? Context Therapeutics' return on equity of -58.76% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Context TherapeuticsN/A -58.76% -55.80% Aerovate Therapeutics N/A -90.19%-77.47% Which has more volatility & risk, CNTX or AVTE? Context Therapeutics has a beta of 1.86, indicating that its share price is 86% more volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Which has higher earnings and valuation, CNTX or AVTE? Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioContext TherapeuticsN/AN/A-$23.96M-$0.31-2.03Aerovate TherapeuticsN/AN/A-$75.52M-$1.70-4.14 Do insiders & institutionals believe in CNTX or AVTE? 14.0% of Context Therapeutics shares are owned by institutional investors. 2.8% of Context Therapeutics shares are owned by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts recommend CNTX or AVTE? Context Therapeutics presently has a consensus target price of $6.00, suggesting a potential upside of 855.41%. Aerovate Therapeutics has a consensus target price of $78.75, suggesting a potential upside of 1,020.20%. Given Aerovate Therapeutics' higher possible upside, analysts clearly believe Aerovate Therapeutics is more favorable than Context Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Context Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Aerovate Therapeutics 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to CNTX or AVTE? In the previous week, Context Therapeutics had 9 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 11 mentions for Context Therapeutics and 2 mentions for Aerovate Therapeutics. Aerovate Therapeutics' average media sentiment score of 1.54 beat Context Therapeutics' score of 1.23 indicating that Aerovate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Context Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Aerovate Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryContext Therapeutics beats Aerovate Therapeutics on 13 of the 16 factors compared between the two stocks. Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTX vs. The Competition Export to ExcelMetricContext TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$56.33M$6.92B$5.61B$8.62BDividend YieldN/A2.54%5.28%4.17%P/E Ratio-0.698.6727.1419.96Price / SalesN/A262.53414.30157.63Price / CashN/A65.8538.2534.64Price / Book0.856.597.074.69Net Income-$23.96M$143.75M$3.23B$248.14M7 Day Performance-5.44%0.67%0.71%0.91%1 Month Performance-23.41%11.92%9.65%5.71%1 Year Performance-68.12%4.33%32.07%14.71% Context Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTXContext Therapeutics3.1068 of 5 stars$0.63-3.8%$6.00+855.4%-67.4%$56.33MN/A-0.697Positive NewsGap UpAVTEAerovate Therapeutics2.0313 of 5 stars$7.25+2.3%$78.75+986.2%-99.1%$210.14MN/A-2.4220News CoveragePositive NewsHigh Trading VolumeYMABY-mAbs Therapeutics3.5911 of 5 stars$4.74+3.0%$15.60+229.1%-61.5%$208.31M$88.66M-8.78150Analyst RevisionACTUActuate TherapeuticsN/A$10.59-11.0%$20.50+93.6%N/A$207.78MN/A0.0010High Trading VolumeENGNenGene2.6423 of 5 stars$3.98+3.6%$23.29+485.1%-67.2%$202.89MN/A-6.8631Earnings ReportGap UpSCPHscPharmaceuticals4.4651 of 5 stars$3.84+5.5%$14.00+264.6%-1.0%$202.72M$41.98M-2.0230Positive NewsCTMXCytomX Therapeutics4.3104 of 5 stars$2.51-5.3%$5.33+112.5%+100.7%$202.36M$147.56M14.76170Positive NewsDRUGBright Minds Biosciences3.3515 of 5 stars$28.32+9.1%$83.25+194.0%+2,552.3%$199.49MN/A-166.58N/APositive NewsAnalyst RevisionGap DownCRGXCARGO Therapeutics2.4255 of 5 stars$4.28+0.7%$15.00+250.5%-73.8%$197.35MN/A-1.00116Positive NewsIPHAInnate Pharma3.1718 of 5 stars$2.14-2.2%$11.00+413.8%-19.5%$197.35M$12.62M0.00220Positive NewsGap DownNBTXNanobiotix2.884 of 5 stars$4.13+0.8%$8.00+93.5%+8.3%$194.85M-$11.61M0.00100Positive NewsShort Interest ↓Gap Up Related Companies and Tools Related Companies AVTE Alternatives YMAB Alternatives ACTU Alternatives ENGN Alternatives SCPH Alternatives CTMX Alternatives DRUG Alternatives CRGX Alternatives IPHA Alternatives NBTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNTX) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
